Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Temporarily not available 1Recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 1KRAS G12V Mutant Advanced Epithelial Cancers 1Hodgkin Disease 1

Interventions

Cyclophosphamide 2064Radiotherapy 1984Cisplatin 1851Carboplatin 1557Gemcitabine 1452Paclitaxel 1320Bevacizumab 1316pembrolizumab 1235Docetaxel 1225Oxaliplatin 1181Capecitabine 1173Fluorouracil 1081Dexamethasone 979Magnetic Resonance Spectroscopy 967Nivolumab 936Rituximab 928Drug Therapy 911Surveys and Questionnaires 898Doxorubicin 845Etoposide 843Radiosurgery 814Blood Specimen Collection 814Irinotecan 783Cytarabine 743fludarabine 723Leucovorin 682Surgical Procedures, Operative 638Lenalidomide 618Biopsy 592fludarabine phosphate 568

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Insulin Infusion Systems × Clear all
NCT05389514 2025-11-20

Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors

Providence Health & Services

Temporarily not available

KRAS G12V Mutant Advanced Epithelial Cancers

NCT06090864 2025-10-20

ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Recruiting
31 enrolled
Lymphoid

Hodgkin Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡